Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

NCT01215565 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped lack of inclusion

Conditions

Hepatocellular Carcinoma
Fibrolamellar Hepatocellular Carcinoma

Interventions

DRUG: Sutent

Sponsor

Assistance Publique - Hôpitaux de Paris